Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
NovavaxNVAX | Open-market sale | 24/12/24–24/12/31 | 25/01/02 | 10,000 sh2 trades | $8.22avg. | $82,208 | −16.2% | |
Rachel K. KingDirector | NovavaxNVAX | Open-market sale | 24/12/13 | 25/01/02 | 4,150 sh | $9.02 | $37,433 | −21.9% |
Young James F.Director | NovavaxNVAX | Open-market sale | 24/06/21 | 24/06/25 | 7,500 sh | $14.09 | $105,675 | −10.8% |
NovavaxNVAX | Open-market sale | 24/06/18 | 24/06/21 | 7,500 sh2 trades | $13.72avg. | $102,880.62 | −9.8% | |
NovavaxNVAX | Open-market sale | 24/06/17 | 24/06/20 | 13,904 sh2 trades | $14.47avg. | $201,164.16 | −17.3% | |
Filip DubovskyPresident, R&D | NovavaxNVAX | Open-market sale | 24/05/14 | 24/05/15 | 47,312 sh | $13.90 | $657,636.8 | −54.8% |
NovavaxNVAX | Open-market buy | 23/03/06–23/03/10 | 23/03/14 | 6,000 sh3 trades | $7.17avg. | $43,020 | +70.8% |